CN1542136A - Preparation method of ascosporine B and its application in the preparation of antitumor and antifungal drugs - Google Patents
Preparation method of ascosporine B and its application in the preparation of antitumor and antifungal drugs Download PDFInfo
- Publication number
- CN1542136A CN1542136A CNA2003101140487A CN200310114048A CN1542136A CN 1542136 A CN1542136 A CN 1542136A CN A2003101140487 A CNA2003101140487 A CN A2003101140487A CN 200310114048 A CN200310114048 A CN 200310114048A CN 1542136 A CN1542136 A CN 1542136A
- Authority
- CN
- China
- Prior art keywords
- compound
- ethyl acetate
- preparation
- bacteria
- fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000000843 anti-fungal effect Effects 0.000 title claims abstract description 8
- 229940121375 antifungal agent Drugs 0.000 title claims abstract description 7
- 229940079593 drug Drugs 0.000 title claims abstract description 7
- 239000003814 drug Substances 0.000 title claims abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 69
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 238000000855 fermentation Methods 0.000 claims abstract description 27
- 230000004151 fermentation Effects 0.000 claims abstract description 27
- 241000894006 Bacteria Species 0.000 claims abstract description 23
- 241000233866 Fungi Species 0.000 claims abstract description 17
- 240000002044 Rhizophora apiculata Species 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 238000010828 elution Methods 0.000 claims abstract description 8
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 5
- 239000012141 concentrate Substances 0.000 claims abstract description 5
- 238000011218 seed culture Methods 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000008103 glucose Substances 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 14
- 244000061456 Solanum tuberosum Species 0.000 claims description 14
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 235000012015 potatoes Nutrition 0.000 claims description 14
- 239000013535 sea water Substances 0.000 claims description 14
- 239000002609 medium Substances 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 8
- 229920001817 Agar Polymers 0.000 claims description 7
- 239000008272 agar Substances 0.000 claims description 7
- 239000003208 petroleum Substances 0.000 claims description 7
- 238000010898 silica gel chromatography Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- -1 (3,5-Dihydroxy-2-octanonyl)-ethyl phenylacetate Chemical compound 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 17
- UVVWQQKSNZLUQA-UHFFFAOYSA-N 2-[3,5-dihydroxy-2-(1-oxooctyl)phenyl]acetic acid ethyl ester Chemical compound CCCCCCCC(=O)C1=C(O)C=C(O)C=C1CC(=O)OCC UVVWQQKSNZLUQA-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000001514 detection method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 4
- 241001602478 Dothiorella sp. Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 2
- 241000223600 Alternaria Species 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000222290 Cladosporium Species 0.000 description 2
- 208000001154 Dermoid Cyst Diseases 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000120622 Rhizophoraceae Species 0.000 description 2
- 241000223259 Trichoderma Species 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000001965 potato dextrose agar Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000012794 white bread Nutrition 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 244000307888 Acanthus ebracteatus Species 0.000 description 1
- 241001674359 Didymosphaeria enalia Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 244000000008 fungal human pathogen Species 0.000 description 1
- 244000000004 fungal plant pathogen Species 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000010267 two-fold dilution method Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
涉及一种来源于红树植物内生真菌—小穴壳菌HTF3的壳囊孢菌素B化合物和制备方法及其在制备抗肿瘤和抗真菌药物中的应用。其方法是内生真菌的种子培养,内生真菌的发酵培养,将上述发酵培养液过滤除去发酵液后得到菌体,菌体烘干后用乙酸乙酯反复浸泡,合并乙酸乙酯,减压浓缩,层析分离,梯度洗脱,收集二者比例为1/1时的洗脱液,减压浓缩即得到该化合物。壳囊孢菌素B化合物可用于制备抗肿瘤药物和抗真菌药物。产量高,达到9mg/g菌体干重,可以用于工业生产。The invention relates to an ascosporine B compound derived from the endophytic fungus of the mangrove plant—Aculetosporum HTF 3 , a preparation method thereof and its application in the preparation of antitumor and antifungal drugs. The method is the seed culture of endophytic fungi, the fermentation culture of endophytic fungi, the above-mentioned fermentation culture liquid is filtered to remove the fermentation liquid to obtain the thallus, the thallus is dried and soaked repeatedly with ethyl acetate, combined with ethyl acetate, decompressed Concentrate, chromatographically separate, gradient elution, collect the eluate when the ratio of the two is 1/1, and concentrate under reduced pressure to obtain the compound. The ascosporin B compound can be used to prepare antitumor drugs and antifungal drugs. The yield is high, reaching 9 mg/g dry weight of bacteria, and can be used in industrial production.
Description
(1)技术领域(1) Technical field
本发明涉及一种来源于红树植物内生真菌—小穴壳菌HTF3(Dothiorella sp.HTF3)的壳囊孢菌素B化合物的制备方法及其在制备抗肿瘤和抗真菌药物中的应用。The invention relates to a preparation method of an ascosporine B compound derived from a mangrove plant endophytic fungus-Aculeella sp.HTF 3 (Dothiorella sp.HTF 3 ) and its application in the preparation of antitumor and antifungal drugs .
(2)背景技术(2) Background technology
红树林是生长在港湾河口地区的淤泥滩涂上的木本植物群落,作为独特的海陆边缘生态系统在自然生态平衡中起着特殊的作用。红树林植物不仅是重要的经济植物,也是民间常用的药用植物,如红树植物老鼠簕(Acanthus ilicifolius)的树皮熬汁可以用于治血尿;角果木(Ceriops tagal)的树皮捣碎可以止血、通便和治疗恶疮,种子榨油可以止痒和治疗癣,还可治疗冻疮等。Mangrove is a woody plant community that grows on mud flats in harbor and estuary areas. As a unique sea and land marginal ecosystem, it plays a special role in the natural ecological balance. Mangrove plants are not only important economic plants, but also commonly used medicinal plants in the folk. For example, the bark of the mangrove plant Acanthus ilicifolius can be used to treat hematuria; It can stop bleeding, lax and treat malignant sores. The oil extracted from the seeds can relieve itching and treat ringworm, and it can also treat frostbite and so on.
红树植物中存在着丰富的内生真菌,有报道认为红树植物的药用成分都是由其内生真菌产生的,不多的文献(1、Brady,S.,Wagenaar,M.W.,Singh,M.,et al.The cytosporonesisolated from an endophytic fungus.Org.Lett.2000,2(25):4043-4046;2、Bandaranayake,W.M..Traditional and medicinal uses of mangroves.Mangroves and Salt Marshes,1998,2:133-148;3、Bandaranayake,W.M..Bioactivities,bioactive compounds and chemicalconstituents of mangrove plants.Wetland Ecology and Management,2002,10:421-452;4、Lin Y.,Wu X.,Deng z.,et al.The metabolites of the mangrove fungus Verruculina enalia No.2606 from a salt lake in the Bahamas.Phytochemistry,2002,59:469-471)报道也已证明红树植物的内生真菌确实可以产生具有新结构和强的生理活性的化合物。但目前国内外在这方面的工作才刚刚开始,为此其研究具有较高的理论价值和实际应用价值。There are abundant endophytic fungi in mangrove plants, and it has been reported that the medicinal components of mangrove plants are all produced by their endophytic fungi, but there are not many documents (1, Brady, S., Wagenaar, M.W., Singh, M., et al. The cytosporonesisolated from an endophytic fungus. Org. Lett. 2000, 2(25): 4043-4046; 2, Bandaranayake, W.M.. Traditional and medicinal uses of mangroves. Mangroves and Salt Marshes, 1998, 2: 133-148; 3. Bandaranayake, W.M.. Bioactivities, bioactive compounds and chemical constituents of mangrove plants. Wetland Ecology and Management, 2002, 10: 421-452; 4. Lin Y., Wu X., Deng z., et al. The metabolites of the mangrove fungus Verruculina enalia No.2606 from a salt lake in the Bahamas. Phytochemistry, 2002, 59: 469-471) reports have also proved that endophytic fungi of mangrove plants can indeed produce new structures and strong physiological active compound. But at present, the work in this field at home and abroad has just begun, so its research has high theoretical value and practical application value.
(3)发明内容(3) Contents of the invention
本发明的目的在于提供一种来源于红树植物内生真菌(cytosporone B)的化合物的分离提取方法以及它在制备抗肿瘤药物和抗真菌药物中的应用。The object of the present invention is to provide a method for separating and extracting compounds derived from mangrove plant endophytic fungi (cytosporone B) and its application in the preparation of antitumor drugs and antifungal drugs.
本发明所用的红树植物内生真菌—小穴壳菌HTF3(Dothiorella sp.HTF3)已保藏于中国典型培养物保藏中心(CCTCC,中国 武汉大学校内),保藏号为CCTCC NO:M203067,保藏日期为2003年8月29日。The mangrove plant endophytic fungus used in the present invention—Dothiorella sp.HTF 3 (Dothiorella sp.HTF 3 ) has been preserved in the China Typical Culture Collection Center (CCTCC, within the campus of Wuhan University, China), and the preservation number is CCTCC NO: M203067, and the preservation date is for August 29, 2003.
本发明所说的壳囊孢菌素B(cytosporone B)化合物的结构式为:The structural formula of said ascosporine B (cytosporone B) compound of the present invention is:
(3,5-二羟基-2-辛酮基)-苯乙酸乙酯 (3,5-Dihydroxy-2-octanonyl)-ethyl phenylacetate
所说的壳囊孢菌素B化合物的制备方法为:The preparation method of said ascosporine B compound is:
1)内生真菌(Dothiorella sp.HTF3)的种子培养:1) Seed culture of endophytic fungi (Dothiorella sp.HTF 3 ):
培养基以g为单位,马铃薯去皮、切碎20,水煮,在过滤后的滤液中加葡萄糖1~3,琼脂1.5~2.0,海水定容至100ml,灭菌,制成试管斜面,挑取菌种接入斜面,室温下培养5~15天;The medium is in g. Peel and chop potatoes for 20 g, boil them in water, add glucose 1-3, agar 1.5-2.0 to the filtered filtrate, sea water to 100ml, sterilize, make a test tube slope, pick Take the strains and insert them into the slant, and cultivate them at room temperature for 5-15 days;
2)内生真菌的发酵培养:2) Fermentation culture of endophytic fungi:
发酵培养基以g为单位:马铃薯去皮、切碎20,水煮,在过滤后的滤液中加葡萄糖1~3,海水定容至100ml,灭菌,将斜面上培养好的菌株挑入发酵培养基,室温下培养5~15天;Fermentation medium in g: peel and chop potatoes for 20 g, boil them in water, add glucose 1-3 to the filtered filtrate, adjust the volume of seawater to 100ml, sterilize, and pick the cultured strains on the slant to ferment Culture medium, cultivated at room temperature for 5 to 15 days;
3)将上述发酵培养液过滤除去发酵液后得到菌体;3) obtaining the thallus after filtering the above-mentioned fermentation culture liquid to remove the fermentation liquid;
4)菌体烘干,用乙酸乙酯反复浸泡,合并乙酸乙酯,减压浓缩,所得的膏状物用硅胶柱层析分离,石油醚/乙酸乙酯=100/0到0/100进行梯度洗脱,收集二者比例为1/1时的洗脱液,减压浓缩即得到该化合物,含量为9mg/g菌体干重。4) Bacteria are dried, soaked repeatedly with ethyl acetate, combined with ethyl acetate, concentrated under reduced pressure, and the resulting paste is separated by silica gel column chromatography, petroleum ether/ethyl acetate=100/0 to 0/100 Gradient elution, collect the eluate when the ratio of the two is 1/1, and concentrate under reduced pressure to obtain the compound with a content of 9 mg/g dry weight of bacteria.
所得该化合物的实验数据为:The experimental data of this compound of gained is:
无色油状物;EMS:m/z(rel.int.):323.3[M+H]+(100),345.3[M+Na]+(11.4),361.2[M+K]+(4.2);1H NMR和13C NMR(400MHz,CDCl3,ppm)见表1。Colorless oil; EMS: m/z (rel.int.): 323.3[M+H] + (100), 345.3[M+Na] + (11.4), 361.2[M+K] + (4.2); See Table 1 for 1 H NMR and 13 C NMR (400 MHz, CDCl 3 , ppm).
本发明所说的壳囊孢菌素B化合物可用于制备抗肿瘤药物,其抗肿瘤活性检测实验如下:Said ascosporin B compound of the present invention can be used for preparing antitumor drug, and its antitumor activity detection experiment is as follows:
1)肿瘤细胞株1) Tumor cell lines
人B淋巴瘤Raji细胞、人口腔皮样癌KB细胞、人成骨肉瘤MG-63细胞、人肺癌A549细胞、人宫颈癌hela细胞等。Human B lymphoma Raji cells, human oral dermoid carcinoma KB cells, human osteosarcoma MG-63 cells, human lung cancer A549 cells, human cervical cancer Hela cells, etc.
表1.壳囊孢菌素B的NMR数据
2)材料2) Material
a MTT(噻唑蓝):a MTT (thiazole blue):
用0.01mol/L的磷酸盐缓冲液(PBS)溶解MTT(Thiazoyl blue)到终浓度5mg/ml,0.22μm微孔滤膜过滤除菌,分装后于4℃避光保存;Dissolve MTT (Thiazoyl blue) in 0.01mol/L phosphate buffered saline (PBS) to a final concentration of 5mg/ml, filter and sterilize with a 0.22μm microporous membrane, and store in a dark place at 4°C after aliquoting;
b SDS裂解液:b SDS lysate:
100g十二烷基磺酸钠(SDS),1N HCL 10ml,加热溶解,蒸馏水定容至1000ml。100g sodium dodecyl sulfonate (SDS), 10ml 1N HCL, heated to dissolve, distilled water to 1000ml.
c 细胞培养基(全培):c cell culture medium (full culture):
一袋10g干粉RMPI 1640(Gibco Co.Ltd.)细胞培养基溶于1L双蒸水中;加入2gNaHCO3搅匀溶解后封口,置于4℃过夜,以自然沉淀除去杂质;次日加入10%-15%已灭活(56℃,30min)的小牛血清及1%多抗母液;混匀后用0.22μm孔径的滤膜过滤除菌。One bag of 10g dry powder RMPI 1640 (Gibco Co.Ltd.) cell culture medium was dissolved in 1L double-distilled water; add 2gNaHCO 3 and stir well to dissolve, then seal, and place at 4°C overnight to remove impurities by natural precipitation; the next day, add 10%- 15% calf serum that has been inactivated (56°C, 30min) and 1% polyclonal antibody stock solution; after mixing, use a filter membrane with a pore size of 0.22 μm to filter and sterilize.
3)化合物cytosporone B的配置3) Configuration of compound cytosporone B
取一定量的壳囊孢菌素B,用甲醇溶解并调整浓度为5mg/ml,0.22μm孔径的滤膜过滤除菌,4℃保存备用。Take a certain amount of ascosporin B, dissolve it with methanol and adjust the concentration to 5 mg/ml, filter and sterilize through a filter membrane with a pore size of 0.22 μm, and store it at 4°C for future use.
4)肿瘤细胞的培养4) Culture of tumor cells
a 细胞活化:a Cell activation:
取一干净烧杯,装入干净温水,水温调至37~40℃;将冻存管从液氮中取出迅速投入温水解冻,并将冻存细胞接入预装有细胞培养基的培养瓶内,在37℃、5%CO2、100%湿度的条件下培养,观察细胞生长情况,及时更换培养液、分瓶。Take a clean beaker, fill it with clean warm water, and adjust the water temperature to 37-40°C; take the cryopreservation tube out of liquid nitrogen and put it into warm water to thaw quickly, and put the frozen cells into a culture bottle pre-filled with cell culture medium. Cultivate under the conditions of 37°C, 5% CO 2 , and 100% humidity, observe the growth of the cells, replace the culture medium in time, and divide the bottles.
b 细胞计数:b cell count:
选对数生成期细胞,胰酶消化,移入离心管中,加全培至10ml,取一滴滴入计数板一侧凹槽中,倒置显微镜下计数。调整细胞数至1×105/ml。Select the cells in the logarithmic generation phase, digest them with trypsin, transfer them to a centrifuge tube, add whole culture to 10ml, take a drop into the groove on the side of the counting plate, and count under an inverted microscope. Adjust the cell number to 1×10 5 /ml.
c 活性检测:c activity detection:
①96孔板在超净工作台内紫外光下照射1h;① The 96-well plate was irradiated with ultraviolet light in the ultra-clean workbench for 1 hour;
②在各孔中加入细胞悬液80μl,37℃、5%CO2、100%湿度的条件下培养24h;② Add 80 μl of cell suspension to each well, and incubate for 24 hours at 37°C, 5% CO 2 , and 100% humidity;
③加入20μl用全培梯度稀释成一系列浓度的溶液,继续培养48h;③ Add 20 μl of solution diluted with a series of concentrations in the whole culture gradient, and continue to cultivate for 48 hours;
④每孔加入MTT溶液10μl,轻轻震摇使颗粒溶解,37℃放置3h;④ Add 10 μl of MTT solution to each well, shake gently to dissolve the particles, and place at 37°C for 3 hours;
⑤取出培养板,每孔加入10%SDS溶液100μl,37℃溶解过夜;⑤ Take out the culture plate, add 100 μl of 10% SDS solution to each well, and dissolve overnight at 37°C;
⑥用酶联反应仪570nm测定各孔吸光值(参比波长为655nm),按下列公式计算抑制率:⑥ Measure the absorbance of each hole with an enzyme-linked reaction instrument at 570nm (the reference wavelength is 655nm), and calculate the inhibition rate according to the following formula:
抑制率=(对照组OD值-实验组OD值)/对照组OD值×100%Inhibition rate = (OD value of the control group - OD value of the experimental group) / OD value of the control group × 100%
⑦以抑制率为纵坐标,受试样品浓度的对数为横坐标作图,求出抑制率为50%时的浓度即为IC50。⑦ Take the inhibition rate as the ordinate and the logarithm of the concentration of the tested sample as the abscissa, and find the concentration at which the inhibition rate is 50%, which is IC 50 .
d 试验结果:d Test results:
Cytosporone B对人B淋巴瘤Raji细胞、人口腔皮样癌KB细胞、人成骨肉瘤MG-63细胞、人肺癌A549细胞、人宫颈癌hela细胞的IC50分别是62.5ng/ml、4μg/ml、1μg/ml、4μg/ml和1μg/ml。The IC 50 of Cytosporone B on human B lymphoma Raji cells, human oral dermoid carcinoma KB cells, human osteosarcoma MG-63 cells, human lung cancer A549 cells, and human cervical cancer Hela cells are 62.5ng/ml and 4μg/ml, respectively , 1 μg/ml, 4 μg/ml and 1 μg/ml.
本发明所说的壳囊孢菌素B化合物可用于制备抗真菌药物,其抗真菌活性检测实验如下:Said ascosporin B compound of the present invention can be used for preparing antifungal drug, and its antifungal activity detection experiment is as follows:
1)真菌指示菌株:1) Fungal indicator strains:
白色假丝酵母菌、黑曲霉菌、木霉菌、镰刀菌、交链孢霉菌、白色面包霉菌、枝孢霉菌Candida albicans, Aspergillus niger, Trichoderma, Fusarium, Alternaria, white bread mold, Cladosporium
2)化合物cytosporone B的配置2) Configuration of compound cytosporone B
取一定量的cytosporone B,用甲醇溶解并调整浓度为1mg/ml,0.22μm孔径的滤膜过滤除菌,4℃保存备用。Take a certain amount of cytosporone B, dissolve it with methanol and adjust the concentration to 1 mg/ml, filter and sterilize through a filter membrane with a pore size of 0.22 μm, and store it at 4°C for later use.
3)活性检测:(最低抑菌浓度MIC的测定)3) Activity detection: (determination of minimum inhibitory concentration MIC)
a 用无菌水将在PDA(马铃薯-葡萄糖-琼脂)斜面培养基上生长的各指示菌洗下,制成孢子浓度为107个/ml的菌悬液,4℃保存备用;a Wash the indicator bacteria grown on the PDA (potato-dextrose-agar) slant medium with sterile water to make a bacterial suspension with a spore concentration of 107 /ml, and store it at 4°C for later use;
b cytosporone B的样品溶液按两倍稀释法,用甲醇稀释成一系列的浓度梯度,取20μl加入到已在超净工作台的紫外灯下照射30min的96孔板中。用超净工作台的风机鼓风吹干甲醇;b Cytosporone B sample solution was diluted with methanol into a series of concentration gradients according to the two-fold dilution method, and 20 μl was added to the 96-well plate that had been irradiated for 30 minutes under the ultraviolet lamp of the ultra-clean workbench. Dry methanol with blower blower of ultra-clean workbench;
c 真菌悬液用PD(马铃薯-葡萄糖)培养基稀释成104个/μl的菌液,取100μl加入到上述96孔板上,25℃培养48h,肉眼观测,没有真菌生成的最小稀释浓度即为MIC。c Dilute the fungal suspension with PD (potato-glucose) medium to 10 4 bacteria/μl, take 100 μl and add it to the above 96-well plate, incubate at 25°C for 48 hours, and observe with the naked eye, the minimum dilution concentration for no fungal formation is for the MIC.
d 实验结果:d Experimental results:
cytosporone B对白色假丝酵母菌、黑曲霉菌、木霉菌、镰刀菌、交链孢霉菌、白色面包霉菌、枝孢霉菌的MIC分别是:0.156mg/ml、0.125mg/ml、0.0625mg/ml、0.0625mg/ml、0.07mg/ml、0.125mg/ml和1mg/ml。The MICs of cytosporone B against Candida albicans, Aspergillus niger, Trichoderma, Fusarium, Alternaria, white bread mold and Cladosporium are: 0.156mg/ml, 0.125mg/ml, 0.0625mg/ml , 0.0625mg/ml, 0.07mg/ml, 0.125mg/ml and 1mg/ml.
综上所述,本发明提供了一类来源于红树林内生真菌的化合物的制备方法,产量高,达到9mg/g菌体干重,可以用于工业生产;该化合物对多种人体肿瘤细胞均表现出较好的抑制作用,可用于制备抗这类肿瘤的药物;该化合物还对人体致病真菌和植物致病真菌有较好的抑制作用,可用于制备这类抗真菌药物。In summary, the present invention provides a method for preparing a compound derived from mangrove endophytic fungi, which has a high yield, reaching 9 mg/g dry weight of bacteria, and can be used in industrial production; the compound is effective on a variety of human tumor cells All exhibit good inhibitory effects, and can be used for preparing anti-tumor drugs; the compound also has good inhibitory effects on human pathogenic fungi and plant pathogenic fungi, and can be used for preparing such antifungal drugs.
(4)具体实施方式(4) specific implementation
实施例1Example 1
以下实施例给出所说的壳囊孢菌素B化合物的制备方法。The following examples show the preparation of said ascosporin B compounds.
1)内生真菌的种子培养:1) Seed culture of endophytic fungi:
将20g马铃薯去皮、切碎,水煮30min,在过滤后的滤液中加葡萄糖1g,琼脂1.6g,50%海水定容至100ml,灭菌,制成试管斜面,挑取菌种接入斜面,25℃下培养10天;Peel and chop 20g of potatoes, boil them in water for 30min, add 1g of glucose, 1.6g of agar, and 50% seawater to 100ml in the filtered filtrate, sterilize, make a test tube slope, and pick the bacteria into the slope , cultivated at 25°C for 10 days;
2)内生真菌的发酵培养:2) Fermentation culture of endophytic fungi:
将20g马铃薯去皮、切碎,水煮30min,在过滤后的滤液中加葡萄糖1.5g,50%海水定容至100ml,灭菌,将斜面上培养好的菌株挑入发酵培养基,26℃下培养8天;Peel and chop 20g of potatoes, boil in water for 30min, add 1.5g of glucose to the filtered filtrate, dilute to 100ml with 50% seawater, sterilize, pick the cultured strains on the slope into the fermentation medium, and keep at 26°C Under culture for 8 days;
3)将上述发酵培养液过滤除去发酵液后得到菌体;3) obtaining the thallus after filtering the above-mentioned fermentation culture liquid to remove the fermentation liquid;
4)菌体烘干,用乙酸乙酯反复浸泡,合并乙酸乙酯,减压浓缩,所得的膏状物用硅胶柱层析分离,石油醚/乙酸乙酯=100/0到0/100进行梯度洗脱,收集二者比例为1/1时的洗脱液,减压浓缩即得到该化合物,含量为9mg/g菌体干重。4) Bacteria are dried, soaked repeatedly with ethyl acetate, combined with ethyl acetate, concentrated under reduced pressure, and the resulting paste is separated by silica gel column chromatography, petroleum ether/ethyl acetate=100/0 to 0/100 Gradient elution, collect the eluate when the ratio of the two is 1/1, and concentrate under reduced pressure to obtain the compound with a content of 9 mg/g dry weight of bacteria.
实施例2Example 2
将20g马铃薯去皮、切碎,水煮30min,在过滤后的滤液中加葡萄糖1.5g,琼脂1.8g,50%海水定容至100ml灭菌,制成试管斜面,挑取菌种接入斜面,30℃下培养8天;再将20g马铃薯去皮、切碎,水煮30min,在过滤后的滤液中加葡萄糖2.5g,50%海水定容至100ml,灭菌,将斜面上培养好的菌株挑入发酵培养基,20℃下培养15天;将上述发酵培养液过滤除去发酵液后得到菌体;菌体烘干后用乙酸乙酯反复浸泡,合并乙酸乙酯,减压浓缩,所得的膏状物用硅胶柱层析分离,石油醚/乙酸乙酯=100/0到0/100进行梯度洗脱,收集二者比例为1/1时的洗脱液,减压浓缩即得到该化合物,含量为9mg/g菌体干重。Peel and chop 20g of potatoes, boil them in water for 30min, add 1.5g of glucose, 1.8g of agar, and 50% seawater to 100ml to sterilize the filtered filtrate, make a test tube slope, and pick the bacteria into the slope , cultivated at 30°C for 8 days; then peeled and chopped 20g of potatoes, boiled them in water for 30min, added 2.5g of glucose to the filtered filtrate, adjusted the volume to 100ml with 50% seawater, sterilized, and cultured on the slant The strains were picked into the fermentation medium and cultured at 20°C for 15 days; the above-mentioned fermentation broth was filtered to remove the fermentation broth to obtain bacteria; after drying, the bacteria were repeatedly soaked in ethyl acetate, combined with ethyl acetate, and concentrated under reduced pressure to obtain The paste was separated by silica gel column chromatography, petroleum ether/ethyl acetate=100/0 to 0/100 for gradient elution, and the eluate when the ratio of the two was 1/1 was collected and concentrated under reduced pressure to obtain the compound, the content of which is 9 mg/g dry weight of bacteria.
实施例3Example 3
将20g马铃薯去皮、切碎,水煮30min,在过滤后的滤液中加葡萄糖2.0g,琼脂1.5g,50%海水定容至100ml,灭菌,制成试管斜面,挑取菌种接入斜面,28℃下培养15天;再将20g马铃薯去皮、切碎,水煮30min,在过滤后的滤液中加葡萄糖2g,50%海水定容至100ml,灭菌,将斜面上培养好的菌株挑入发酵培养基,25℃下培养10天;将上述发酵培养液过滤除去发酵液后得到菌体;菌体烘干后用乙酸乙酯反复浸泡,合并乙酸乙酯,减压浓缩,所得的膏状物用硅胶柱层析分离,石油醚/乙酸乙酯=100/0到0/100进行梯度洗脱,收集二者比例为1/1时的洗脱液,减压浓缩即得到该化合物,含量为9mg/g菌体干重。Peel and chop 20g of potatoes, boil them in water for 30min, add 2.0g of glucose, 1.5g of agar, and 50% seawater to 100ml in the filtered filtrate, sterilize it, make it into a test tube slope, and pick the bacteria into it Slope, cultivated at 28°C for 15 days; then peeled and chopped 20g of potatoes, boiled in water for 30min, added 2g of glucose to the filtrate after filtration, adjusted to 100ml with 50% sea water, sterilized, and cultured on the slope The strains were picked into the fermentation medium and cultured at 25°C for 10 days; the above-mentioned fermentation broth was filtered to remove the fermentation broth to obtain bacteria; after drying, the bacteria were repeatedly soaked in ethyl acetate, combined with ethyl acetate, and concentrated under reduced pressure to obtain The paste was separated by silica gel column chromatography, petroleum ether/ethyl acetate=100/0 to 0/100 for gradient elution, and the eluate when the ratio of the two was 1/1 was collected and concentrated under reduced pressure to obtain the compound, the content of which is 9 mg/g dry weight of bacteria.
实施例4Example 4
将20g马铃薯去皮、切碎,水煮30min,在过滤后的滤液中加葡萄糖2.5g,琼脂2.0g,50%海水定容至100ml,灭菌,制成试管斜面,挑取菌种接入斜面,20℃下培养12天;再将20g马铃薯去皮、切碎,水煮30min,在过滤后的滤液中加葡萄糖1g,50%海水定容至100ml,灭菌,将斜面上培养好的菌株挑入发酵培养基,30℃下培养12天:将上述发酵培养液过滤除去发酵液后得到菌体;菌体烘干后用乙酸乙酯反复浸泡,合并乙酸乙酯,减压浓缩,所得的膏状物用硅胶柱层析分离,石油醚/乙酸乙酯=100/0到0/100进行梯度洗脱,收集二者比例为1/1时的洗脱液,减压浓缩即得到该化合物,含量为9mg/g菌体干重。Peel and chop 20g of potatoes, boil them in water for 30min, add 2.5g of glucose, 2.0g of agar, and 50% seawater to 100ml in the filtered filtrate, sterilize, make a test tube slope, pick the strains and insert them Slope, cultured at 20°C for 12 days; then peeled and chopped 20g of potatoes, boiled in water for 30min, added 1g of glucose to the filtrate after filtration, adjusted the volume to 100ml with 50% sea water, sterilized, and cultured on the slope The strains were picked into the fermentation medium and cultured at 30°C for 12 days: the above-mentioned fermentation culture liquid was filtered to remove the fermentation liquid to obtain the bacteria; the bacteria were dried and soaked repeatedly in ethyl acetate, combined with ethyl acetate, concentrated under reduced pressure, and The paste was separated by silica gel column chromatography, petroleum ether/ethyl acetate=100/0 to 0/100 for gradient elution, and the eluate when the ratio of the two was 1/1 was collected and concentrated under reduced pressure to obtain the compound, the content of which is 9 mg/g dry weight of bacteria.
实施例5Example 5
将20g马铃薯去皮、切碎,水煮30min,在过滤后的滤液中加葡萄糖3.0g,琼脂1.7g,50%海水定容至100ml,灭菌,制成试管斜面,挑取菌种接入斜面,23℃下培养5天;再将20g马铃薯去皮、切碎,水煮30min,在过滤后的滤液中加葡萄糖3.0g,50%海水定容至100ml,灭菌,将斜面上培养好的菌株挑入发酵培养基,28℃下培养5天;将上述发酵培养液过滤除去发酵液后得到菌体;菌体烘干后用乙酸乙酯反复浸泡,合并乙酸乙酯,减压浓缩,所得的膏状物用硅胶柱层析分离,石油醚/乙酸乙酯=100/0到0/100进行梯度洗脱,收集二者比例为1/1时的洗脱液,减压浓缩即得到该化合物,含量为9mg/g菌体干重。Peel and chop 20g of potatoes, boil them in water for 30min, add 3.0g of glucose, 1.7g of agar, and 50% seawater to 100ml in the filtered filtrate, sterilize it, make it into a test tube slope, and pick the strains into it Slope, cultured at 23°C for 5 days; then peeled and chopped 20g of potatoes, boiled in water for 30min, added 3.0g of glucose to the filtrate after filtration, adjusted to 100ml with 50% sea water, sterilized, and cultured on the slope The strains were picked into the fermentation medium and cultured at 28°C for 5 days; the above-mentioned fermentation broth was filtered to remove the fermentation broth to obtain the cells; after drying, the cells were repeatedly soaked in ethyl acetate, combined with ethyl acetate, concentrated under reduced pressure, The obtained paste was separated by silica gel column chromatography, and petroleum ether/ethyl acetate = 100/0 to 0/100 for gradient elution, and the eluate when the ratio of the two was 1/1 was collected and concentrated under reduced pressure to obtain The content of the compound is 9mg/g dry weight of bacteria.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310114048 CN1243100C (en) | 2003-11-08 | 2003-11-08 | Method for production of cytosporasp B and the use in preparation of anti-tumor and antifungal medicine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310114048 CN1243100C (en) | 2003-11-08 | 2003-11-08 | Method for production of cytosporasp B and the use in preparation of anti-tumor and antifungal medicine |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100856732A Division CN1322861C (en) | 2003-11-08 | 2003-11-08 | Application of ascosporine B in the preparation of antifungal drugs |
CNB2005100856747A Division CN1305466C (en) | 2003-11-08 | 2003-11-08 | Application of Cytospora bacterin B in preparation of antineoplastic medicine |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1542136A true CN1542136A (en) | 2004-11-03 |
CN1243100C CN1243100C (en) | 2006-02-22 |
Family
ID=34337024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200310114048 Expired - Fee Related CN1243100C (en) | 2003-11-08 | 2003-11-08 | Method for production of cytosporasp B and the use in preparation of anti-tumor and antifungal medicine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1243100C (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1319933C (en) * | 2005-08-15 | 2007-06-06 | 厦门大学 | Compound essence of Dothiorella and its preparation method and uses |
CN102579373A (en) * | 2012-03-26 | 2012-07-18 | 山东大学 | Amoitone B nano crystallization preparation and preparation method thereof |
CN101407459B (en) * | 2008-11-18 | 2013-03-27 | 厦门大学 | Monohydroxy-2-acyl phenylacetate, and preparation and use thereof |
-
2003
- 2003-11-08 CN CN 200310114048 patent/CN1243100C/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1319933C (en) * | 2005-08-15 | 2007-06-06 | 厦门大学 | Compound essence of Dothiorella and its preparation method and uses |
CN101407459B (en) * | 2008-11-18 | 2013-03-27 | 厦门大学 | Monohydroxy-2-acyl phenylacetate, and preparation and use thereof |
CN102579373A (en) * | 2012-03-26 | 2012-07-18 | 山东大学 | Amoitone B nano crystallization preparation and preparation method thereof |
CN102579373B (en) * | 2012-03-26 | 2013-05-08 | 山东大学 | Amoitone B nano crystallization preparation and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1243100C (en) | 2006-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101294137B (en) | A kind of Arthrospora strain and its use | |
CN113444131B (en) | N-acetylglucosamine compounds, and preparation method and application thereof | |
CN114606134B (en) | A kind of sponge symbiont fungus and its application in the preparation of xanthanquinone compounds | |
CN101234951B (en) | Biphenyl compounds and their preparation methods and applications | |
CN1219879C (en) | Hainan variety of lilac grey streptomycete and method for preparing agricultural antibiotic from variety | |
CN110863021B (en) | Preparation method and application of cytochalasin compound | |
CN103274915A (en) | Diterpenoid compounds libertellenone G and libertellenone H with antineoplastic activities and application thereof | |
CN102659802B (en) | Application in terms of the preparation method of coumarin Neolignans and anti-marime fouling thereof | |
CN118344977B (en) | Separation and application of benthopus japonicus bark endophytic fungi NEMANIA SP YAFEF112,112 | |
CN1542136A (en) | Preparation method of ascosporine B and its application in the preparation of antitumor and antifungal drugs | |
CN101029038A (en) | Benzofurantone compound, its production and use | |
CN109400444B (en) | Sesquiterpenoids for inhibiting plant pathogenic fungi and preparation method thereof | |
CN110003153A (en) | A kind of benzofuran compounds and its preparation method and application | |
CN1319933C (en) | Compound essence of Dothiorella and its preparation method and uses | |
CN108707090A (en) | One kind aromatic compound containing chlorine and its preparation method and application | |
CN1158298C (en) | Antineoplastic compound and its prepn and medicinal use | |
CN1218928C (en) | Doxerolone compound, preparation method and application thereof | |
CN1322861C (en) | Application of ascosporine B in the preparation of antifungal drugs | |
CN102786528A (en) | Polyoxybiotic alkali compound as well as preparation method and application thereof | |
CN1305466C (en) | Application of Cytospora bacterin B in preparation of antineoplastic medicine | |
CN101235040B (en) | Phomopsis compound and its preparation method and application | |
CN113402471B (en) | Siderophore compounds derived from endophytic fungi and preparation method and application | |
CN104059038A (en) | Sesquiterpene compounds and application thereof | |
CN104017736A (en) | Rhizopus nigricans polysaccharide with antitumor activity and application thereof | |
CN108794502A (en) | A kind of trichothecene compounds and its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060222 Termination date: 20091208 |